DIO TREE LTD
General Data
Reg Number
516693314
Sector
Biomed
Established
2022
No. of Employees
3
Stage
R&D
Additional Funding
0
Description
DioTree is passionately dedicated to developing innovative treatment for high grade serous ovarian cancer (HGSOC), one of the deadliest human cancers with an extremely poor prognosis. Our groundbreaking approach involves the development of a first-of-its-
Technology
The company's innovative technology involves a series of small molecules. Those Molecules specifically target the DIO3 enzyme which is highly expressed in various aggressive cancers, including high grade serous ovarian cancer (HGSOC). DIO3 is an attractive target for inhibition since it is responsible for breaking down thyroid hormones, including the biological hormone T3. Because T3 has anti-cancer functions, many tumors express this enzyme, thereby facilitating the division of cancer cells.
Targeted Customers
Ovarian Cancer Patients
Management personnel
Sarit Batsir - CEO
Winning details
Route name
Winning year
Technological Incubators 2020
Technological Incubators 2020
2024
Technological Incubators 2020
Technological Incubators 2020
2025